赛诺菲喜保宁用法用量
(Vigabatrin tablets) was first synthesized in 1974. It is a gamma-aminobutyric acid (GABA) analogue that can specifically bind to aminotransferase to produce an inhibitory effect, thereby increasing the concentration of GABA in the brain and cortical nodules, producing anti-epileptic effects. In order for patients to continue to benefit from it, patients must master the usage and dosage of Sanofi Vigabatrin.
Sanofi Vigabatrin usage and dosage: For adults, the recommended dose of Vigabatrin for anti-epilepsy is 3g per day, taken in divided doses. The dose should be increased according to the clinical effect at a rate of 0.5-1g per day to 4g per day (or 50mg/kg per day), which is effective for complex partial seizures of epilepsy (with or without generalized tonic-clonic seizures). For patients whose creatinine clearance is less than or equal to 60ml/min, it is recommended to reduce the dose. Generally speaking, Vigabatrin has less toxicity and side effects. Mainly causing drowsiness and reducing anticonvulsant effect. Interactions with other drugs are unknown.
For children, the general usage of Vigabatrin is: for children aged 3-9 years, the recommended dose is 1g per day, taken in 2 divided doses; for older children, 2g per day, taken in 2 divided doses. West syndrome: Average oral dose is 100 mg/kg daily (range 50-150 mg/kg). Before and after medication, patients need to store Sanofi Vigabatrin in a dry place at 20-25 degrees, shielded from light and airtight, and be careful to keep it out of reach of children.
As one of the growth platforms for sustainable development, Sanofi's R&D department is committed to providing treatment solutions for patients. It has always inherited a long history and continued to forge ahead. When patients purchase and use Sanofi, they must choose regular overseas medical service institutions to purchase drugs, and they must also master the correct medication methods to ensure continued benefit from it. Once adverse reactions occur during medication, you should understand and take appropriate measures to deal with them.
Recommended hot articles: /newsDetail/93733.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)